Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
Based on BioNTech’s deep expertise in mRNA vaccine development and in-house manufacturing capabilities, the team and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
BioNTech on the cooperation with MIG Capital:
“When MIG invested in our transformative technology approach in 2008, no one could have predicted that mRNA technology would save millions of lives in the Corona pandemic more than a decade later. We thank MIG and the other high technology investors for seeing the potential in the rapid fusion of bioinformatics, robotics, and artificial intelligence with life sciences for the development of precise, effective, and low-cost individualized immunotherapies and supporting it with all their expertise and financial resources.” Prof. Dr. Ugur Sahin, CEO and Co-Founder of BioNTech